Ultragenyx Pharmaceutical Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Ultragenyx Pharmaceutical Inc. on February 20, 2015, reporting events occurring on that date. The filing addresses corporate governance changes specifically regarding the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel appointments and does not contain financial performance data.
Material Changes
- Board Appointment: Michael Narachi was appointed as a Class II director effective February 20, 2015.
- Board Structure: The size of the Board was fixed at six directors, comprising one Class I director, three Class II directors, and two Class III directors.
- Term Duration: Mr. Narachi's term is set to expire at the 2015 annual meeting of stockholders.
Management Commentary and Background
Mr. Narachi brings extensive industry experience to the Board. He currently serves as President and CEO of Orexigen Therapeutics Inc. (since March 2009) and Chairman of Celladon Corporation. His prior roles include Chairman and CEO of Ren Pharmaceuticals, Inc., and a 20-year career at Amgen Inc., where he held senior positions including Vice President of Development and General Manager of the Anemia Business. He also serves on the boards of PhRMA and BIO.
Key Facts for Investor Verification
- Confirm the effective date of Michael Narachi's directorship (February 20, 2015).
- Verify the new total composition of the Board of Directors (6 members).
- Review Mr. Narachi's current executive roles at Orexigen Therapeutics Inc. and Celladon Corporation for potential conflicts of interest.
- Note that this filing contains no financial results or operational updates.